Georgia readers may be concerned to learn that, according to a new study, certain medications that are used to treat high blood pressure could increase a postmenopausal woman's risk of getting pancreatic cancer. Chicago's American Association for Cancer Research presented these findings at a symposium in April 2018.
In the study, researchers followed the health histories of 145,000 women who participated in the Women's Health Initiative. These women were all postmenopausal and ranged in age from 50 to 79 at the beginning of the study. Their use of medications, including blood pressure drugs, was monitored from 1993 until 1998.
Researchers found that 800 of the women had been diagnosed with pancreatic cancer by 2014. They also found that the individuals who took a short-acting calcium channel blocker (CCB), experienced a 66 percent increase in their risk of developing pancreatic cancer. The women who took a CCB for three years or longer experienced a 107 percent increase in their risk of developing the disease. The study found no link between pancreatic cancer and longer-acting CCB drugs, beta-blockers, ACE inhibitors and diuretic drugs. Short-acting CCB drugs are marketed under the brand names Adalat CC, Cardene IV, Cardizem and Procardia. In the United States, the fourth leading cause of cancer-related deaths is pancreatic cancer.
Patients who are harmed by prescription medications may have grounds to file a medical malpractice lawsuit for damages. These damages could include medical costs, pain and suffering and other related losses. If a prescription drug kills a patient, the victim's family could also sue for damages, including medical costs before death, funeral expenses, lost income and loss of companionship. Victims could learn more about the lawsuit process by speaking to a medical malpractice attorney.